The claim: metformin is the closest thing we have to a longevity drug. It is cheap, hundreds of millions of people have taken it, and one famous study found diabetics on it outlived people without diabetes. So maybe it slows aging in everyone.
Here is what the human evidence actually shows.
1. The famous finding is observational, and confounded.
Bannister et al. 2014 (Diabetes Obes Metab, doi:10.1111/dom.12354) used UK general-practice records: 78,241 people started on metformin, 12,222 on a sulfonylurea, matched against 90,463 people without diabetes. Adjusted median survival was about 15% higher in the metformin group than in the non-diabetic controls, and 38% lower in the sulfonylurea group.
That is the origin of "metformin makes diabetics live longer than non-diabetics." But the study is retrospective, and the comparison does a lot of work: the controls were people off the drug entirely, and healthy-user bias plus who gets which drug can move mortality without metformin touching aging at all. It is a hypothesis, not proof.
2. The best human trial so far moves a biomarker, not an outcome.
A 2026 randomized, placebo-controlled trial (Mech Ageing Dev, PMID 42692117) gave metformin 500 mg twice daily or placebo for 24 weeks to 127 people aged 30 to 60 with prediabetes. Metformin increased leukocyte telomere length significantly (mean change +0.247 vs +0.036 units, 29.6% vs 4.4% elongation, between-group p<0.0001) and shifted telomerase and longevity-gene readouts.
That is real, and it is randomized. It is also one small, short trial in a single population, and the endpoint is a blood biomarker, not aging, disease, or death. Telomere length is a readout people still argue about. It is not "living longer."
3. The trial that could settle it has not reported.
TAME (Targeting Aging with Metformin) was designed exactly to test whether metformin delays age-related disease in people. 2026 reviews still describe it as the trial that "could lead to a paradigm shift" (Aging, doi:10.18632/aging.206407; Pharmacol Res, doi:10.1016/j.phrs.2026.108443). In other words, it has not given us the answer yet.
Verdict: the claim overshoots. The mechanisms are plausible (AMPK activation, mTOR inhibition, autophagy in animals), and there is one short randomized human trial showing a biomarker shifts. But no human trial has shown metformin delays aging, prevents age-related disease, or extends lifespan. The strongest human evidence is observational and confounded. "Metformin is a longevity drug" is a bet on a trial that has not finished.
Sources
- Bannister CA et al., "Can people with type 2 diabetes live longer than those without?", Diabetes Obes Metab 2014, doi:10.1111/dom.12354 (PMID 25041462)
- "Metformin therapy increases leukocyte telomere length, telomerase activity, and longevity gene expression in Asian Indians with prediabetes", Mech Ageing Dev 2026, doi:10.1016/j.mad.2026.112241 (PMID 42692117)
- "Geroprotective potential of anti-diabetic medications", Pharmacol Res 2026, doi:10.1016/j.phrs.2026.108443 (PMID 42710703)
- "Metformin at the convergence of aging and longevity", Aging 2026, doi:10.18632/aging.206407 (PMID 42579881)
If I got something wrong, say so: 7ens@ilands.app, or leave a comment below.